These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

317 related items for PubMed ID: 20551193

  • 1. Assessment of intravenous immunoglobulin non-responders in Kawasaki disease.
    Hwang JY, Lee KY, Rhim JW, Youn YS, Oh JH, Han JW, Lee JS, Burgner D.
    Arch Dis Child; 2011 Nov; 96(11):1088-90. PubMed ID: 20551193
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. N-terminal pro-brain natriuretic peptide and risk of coronary artery lesions and resistance to intravenous immunoglobulin in Kawasaki disease.
    Yoshimura K, Kimata T, Mine K, Uchiyama T, Tsuji S, Kaneko K.
    J Pediatr; 2013 Jun; 162(6):1205-9. PubMed ID: 23290510
    [Abstract] [Full Text] [Related]

  • 6. Intravenous immunoglobulin therapy induces neutrophil apoptosis in Kawasaki disease.
    Tsujimoto H, Takeshita S, Nakatani K, Kawamura Y, Tokutomi T, Sekine I.
    Clin Immunol; 2002 May; 103(2):161-8. PubMed ID: 12027421
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Elevated granulocyte colony-stimulating factor levels predict treatment failure in patients with Kawasaki disease.
    Abe J, Ebata R, Jibiki T, Yasukawa K, Saito H, Terai M.
    J Allergy Clin Immunol; 2008 Nov; 122(5):1008-1013.e8. PubMed ID: 18930517
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Immunoglobulin failure and retreatment in Kawasaki disease.
    Durongpisitkul K, Soongswang J, Laohaprasitiporn D, Nana A, Prachuabmoh C, Kangkagate C.
    Pediatr Cardiol; 2003 Nov; 24(2):145-8. PubMed ID: 12457253
    [Abstract] [Full Text] [Related]

  • 16. Persistent monocytosis after intravenous immunoglobulin therapy correlated with the development of coronary artery lesions in patients with Kawasaki disease.
    Kuo HC, Wang CL, Liang CD, Yu HR, Chen HH, Wang L, Yang KD.
    J Microbiol Immunol Infect; 2007 Oct; 40(5):395-400. PubMed ID: 17932598
    [Abstract] [Full Text] [Related]

  • 17. Importance of C-reactive protein level in predicting non-response to additional intravenous immunoglobulin treatment in children with Kawasaki disease: a retrospective study.
    Iwashima S, Kimura M, Ishikawa T, Ohzeki T.
    Clin Drug Investig; 2011 Oct; 31(3):191-9. PubMed ID: 21456105
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The relationship of eosinophilia to intravenous immunoglobulin treatment failure in Kawasaki disease.
    Kuo HC, Yang KD, Liang CD, Bong CN, Yu HR, Wang L, Wang CL.
    Pediatr Allergy Immunol; 2007 Jun; 18(4):354-9. PubMed ID: 17584314
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.